This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Harvey, P. W. Articles by Springall, C. J. Search for Related Content PubMed PubMed Citation Articles by Harvey, P. W. Articles by Springall, C. J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Breast Cancer Prostate Cancer Social Bookmarking                         What's this?

Adverse effects of prolactin in rodents and humans: breast and prostate cancer

Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, UK, philip.harvey{at}covance.com

David J. Everett

Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, UK

Christopher J. Springall

Department of Toxicology, Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire, UK

Drugs and chemicals shown to induce mammary carcinogenesis in the rat/rodent via prolactin excess have traditionally been argued to pose little or no risk to humans in a regulatory toxicology context. The basis for this assumption is reviewed and placed into context with new evidence in humans that prolactin may be a tumour promoter in the breast and prostate. This evidence includes epidemiology, patient studies involving endocrine evaluation and molecular biology in human cells. It is concluded that hyperprolactinaemia is associated with an increase in breast cancer risk in both post and premenopausal women, that rat carcinogenicity studies are predictive of the human response, and that in a regulatory toxicology context prolactin-induced mammary tumours from nongenotoxic drugs and chemicals are an adverse effect that should not be ignored. More evidence is required concerning prostate cancer risk but molecular biology indicates that prolactin also induces prostate cell proliferation and inhibits apoptosis, which are similar to the responses observed in breast cancer cells.

Key Words: prolactin • breast cancer • prostate cancer • carcinogenesis • mammary • tumour • hyperprolactinaemia • rat • human • endocrine disruption

Journal of Psychopharmacology, Vol. 22, No. 2 suppl, 20-27 (2008)
DOI: 10.1177/0269881107082624


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]

				D. Kohen and H. J. Wildgust The evolution of hyperprolactinaemia as an entity in psychiatric patients J Psychopharmacol, March 1, 2008; 22(2_suppl): 6 - 11. [Abstract] [PDF]

				C. Bushe, D. Yeomans, T. Floyd, and S. M Smith Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics J Psychopharmacol, March 1, 2008; 22(2_suppl): 56 - 62. [Abstract] [PDF]

				J. Walters and I. Jones Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder J Psychopharmacol, March 1, 2008; 22(2_suppl): 82 - 89. [Abstract] [PDF]